{"id":478184,"date":"2020-04-07T11:18:01","date_gmt":"2020-04-07T11:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478184"},"modified":"2020-04-07T11:18:01","modified_gmt":"2020-04-07T11:18:01","slug":"shigella-infections-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/shigella-infections-epidemiology-forecast-to-2030_478184.html","title":{"rendered":"Shigella Infections Epidemiology Forecast to 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1586236120.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Shigella Infections Epidemiology Forecast to 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1586236120.jpeg\" alt=\"Shigella Infections Epidemiology Forecast to 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8216;Shigella Infections &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Shigella Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight<\/strong> launched a new report on&nbsp;<a rel=\"nofollow\" href=\"https:\/\/delveinsight.com\/report-store\/shigella-infections-epidemiology-forecast\" target=\"_blank\">Shigella Infections &#8211; Epidemiology Forecast to 2030<\/a>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;<strong>Shigella Infections &#8211; Epidemiology Forecast to 2030<\/strong>&#8216; report delivers an in-depth understanding of the disease, historical and forecasted Shigella Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c649722b55a34b10955a421638ec1113.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&#8220;Shigella infections or Shigellosis causes approximately 450,000 cases of diarrhoea in the United States annually.&#8221;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report:<br \/><\/strong>1.&nbsp;The Shigella Infections report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<br \/>2. The Shigella Infections Epidemiology Report and Model provide an overview of the risk factors and global trends of Shigella Infections in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<br \/>3. The report provides insight about the historical and forecasted patient pool of Shigella Infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<br \/>4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<br \/>5. The report assesses the disease risk and burden and highlights the unmet needs of Shigella Infections<br \/>6. The report provides the segmentation of the Shigella Infections epidemiology<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:<\/strong>&nbsp;https:\/\/delveinsight.com\/sample-request\/shigella-infections-epidemiology-forecast<\/p>\n<p style=\"text-align: justify;\"><strong>Reasons to buy:<\/strong><br \/>1. The Shigella Infections Epidemiology report will allow the user to &#8211;<br \/>2. Develop business strategies by understanding the trends shaping and driving the global Shigella Infections market<br \/>3. Quantify patient populations in the global Shigella Infections market to improve product design, pricing, and launch plans<br \/>4. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Shigella Infections therapeutics in each of the markets covered<br \/>5. Understand the magnitude of Shigella Infections population by its epidemiology<br \/>6. The Shigella Infections Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<br \/><\/strong>1.&nbsp;Key Insights&nbsp;<br \/>2. Executive Summary of Shigella Infections<br \/>3.&nbsp;Shigella Infections: Disease Background and Overview<br \/>4.&nbsp;Patient Journey<br \/>5.&nbsp;Epidemiology and Patient Population<br \/>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<br \/>7.&nbsp;KOL Views<br \/>8.&nbsp;Unmet Needs<br \/>9.&nbsp;&nbsp;Appendix<br \/>10.&nbsp;DelveInsight Capabilities<br \/>11.&nbsp;Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight:<\/strong> <br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=shigella-infections-epidemiology-forecast-to-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=shigella-infections-epidemiology-forecast-to-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Shigella Infections &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Shigella Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/shigella-infections-epidemiology-forecast-to-2030_478184.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-478184","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/478184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=478184"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/478184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=478184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=478184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=478184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}